ReviewNature cancer2022
Cancer vaccines: the next immunotherapy frontier.
Review in Nature cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 420 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
420 citing papers in PubMed.
- Oligosaccharide adjuvant-deferred antigen endocytosis promotes cross-presentation.Bioactive materials · 2027Article
- DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8Oncoimmunology · 2026Article
- A naphthyl polymer with STING-activating property for antigen and adjuvant co-delivery to achieve potent cancer immunotherapy.Bioactive materials · 2026Article
- GSH-responsive nanovaccine triggers immunogenic cell death and potent memory T cell immunity for durable, recurrence-free tumor eradication.Bioactive materials · 2026Article
- Nanotechnology-enabled precision targeting of lung cancer stem cells: Recent developments and therapeutic implications.Stem cell reviews and reports · 2026Review
- Carrier-free nanomodulators reprogramming acetate metabolism for cancer photo-immunotherapy via c-Myc inhibition-induced closed-loop regulatory circuit.Materials today. Bio · 2026Article
- Recoding by NNature communications · 2026Article
- Spatial biology reveals altered macrophage states in immunosuppressed non-melanoma skin cancer.Cell · 2026Article
- SARS-CoV-2-specific T cells cross-react with tumor-associated antigens via molecular mimicry.Journal of translational medicine · 2026Article
- An integrated nanopore-microfluidic platform for low-voltage electroporation of delivering self-amplifying RNA into dendritic cells.Microsystems & nanoengineering · 2026Article
- Dual Drug-Loaded Enzyme-Responsive Liposomes Exert Specific Modulation on Liver Cancer Cells and Tumor-Associated Macrophages In Vitro.Pharmaceutics · 2026Article
- Supramolecular STING-Hydrogel Spatiotemporally Boosts Tumor-Derived Extracellular Vesicle-Based Personalized Vaccine for Enhanced Cancer Immunotherapy.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics.Signal transduction and targeted therapy · 2026Review
- Metal-phenolic networks: a promising strategy for cancer immunotherapy.Journal of translational medicine · 2026Review
- In vivo engineering tumor cells to a universal "all-in-one" cancer vaccine with full antigen spectrum.Science advances · 2026Article
- Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives.Molecular cancer · 2026Review
- Engineering an immuno-nanoprodrug: Photo-controlled pyroptosis synergizing with acid-activatable immunometabolic blockade for potent cancer immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
- Immunopeptidomics-guided identification of functional neoantigens in non-small cell lung cancer.NPJ precision oncology · 2026Article
- Hallmarks and correlates of effective adoptive cell immunotherapy for cancer.Nature reviews. Immunology · 2026Review
- Engineered 3D-Lattice Microneedle Array Patches for Enhanced Nanovaccine Delivery to Dendritic Cells in Cancer Immunotherapy.ACS nano · 2026Article
360 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
After several decades, therapeutic cancer vaccines now show signs of efficacy and potential to help patients resistant to other standard-of-care immunotherapies, but they have yet to realize their full potential and expand the oncologic armamentarium. Here, we classify cancer vaccines by what is known of the included antigens, which tumors express those antigens and where the antigens colocalize with antigen-presenting cells, thus delineating predefined vaccines (shared or personalized) and anonymous vaccines (ex vivo or in situ). To expedite clinical development, we highlight the need for accurate immune monitoring of early trials to acknowledge failures and advance the most promising vaccines.
Indexed as
Identifiers
35999309What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.